Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Mineralys Therapeutics to “Strong Sell”, despite the broader analyst consensus remaining “Moderate Buy” with a $49.33 price target.
• Mineralys reported a substantial second-quarter earnings miss, losing $2.85 per share versus the expected $0.55 loss. Shares opened at $25.64, down 1.7%, and analysts expect continued losses for the full year.
• Insiders sold approximately $5.6 million of stock over the past 90 days, while institutional investors own 84.46% of the company. The company’s main potential catalyst remains lorundrostat, which has a December 22, 2026 FDA decision target.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday.

MLYS has been the subject of a number of other reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. TD Cowen assumed coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They issued a "buy" rating on the stock. Jefferies Financial Group reaffirmed a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, HC Wainwright reiterated a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.33.

Mineralys Therapeutics Stock Down 1.7%

Shares of NASDAQ MLYS opened at $25.64 on Friday. The company has a current ratio of 34.46, a quick ratio of 44.33 and a debt-to-equity ratio of 0.18. The business has a 50-day moving average of $26.48 and a 200-day moving average of $27.54. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -6.05 and a beta of 0.68. Mineralys Therapeutics has a 12 month low of $14.16 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Sell-side analysts expect that Mineralys Therapeutics will post -3.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the transaction, the chief executive officer owned 614,321 shares in the company, valued at $16,058,350.94. This trade represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 2,170 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.09, for a total transaction of $58,785.30. Following the completion of the sale, the insider directly owned 51,384 shares of the company's stock, valued at $1,391,992.56. This represents a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 217,313 shares of company stock worth $5,624,488 over the last 90 days. Company insiders own 18.94% of the company's stock.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock worth $271,000 after acquiring an additional 702 shares during the last quarter. Navalign LLC bought a new stake in Mineralys Therapeutics in the fourth quarter valued at approximately $33,000. Velan Capital Investment Management LP lifted its position in Mineralys Therapeutics by 0.6% in the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company's stock valued at $6,659,000 after purchasing an additional 1,000 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after purchasing an additional 1,107 shares during the period. Finally, KBC Group NV purchased a new stake in shares of Mineralys Therapeutics during the first quarter valued at approximately $33,000. Institutional investors own 84.46% of the company's stock.

Key Stories Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source